These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23530420)

  • 1. [Clinical and experimental research of immunomodulatory effect of amisulpride].
    Vetlugina TP; Lobacheva OA; Al'perina EL; Zhukova EN; Semke AV; Nikitina VB; Cheĭdo MA; Idova GV
    Vestn Ross Akad Med Nauk; 2012; (12):13-7. PubMed ID: 23530420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM; Rein W; Fleurot O
    Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpride: a review of its efficacy in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
    Burns T; Bale R
    J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Engel RR; Kissling W
    Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.
    Herrera-Estrella M; Apiquian R; Fresan A; Sanchez-Torres I
    BMC Psychiatry; 2005 May; 5():22. PubMed ID: 15869707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study].
    Rzewuska M; Kuczyński W; Luks M
    Psychiatr Pol; 2004; 38(3):453-68. PubMed ID: 15199655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride.
    Nuss P; Tessier C
    Curr Med Res Opin; 2010 Apr; 26(4):787-801. PubMed ID: 20121655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus on the Practical Use of Amisulpride, an Atypical Antipsychotic, in the Treatment of Schizophrenia.
    Lecrubier Y; Azorin M; Bottai T; Dalery J; Garreau G; Lempérière T; Lisoprawski A; Petitjean F; Vanelle JM
    Neuropsychobiology; 2001; 44(1):41-6. PubMed ID: 11408792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of antipsychotic amisulpride on immune reactivity].
    Idova GV; Al'perina EL; Lobacheva OA; Zhukova EN; Cheĭdo MA; Meniavtseva TA; Vetlugina TP
    Eksp Klin Farmakol; 2013; 76(5):14-7. PubMed ID: 23901463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan.
    Hwang TJ; Lee SM; Sun HJ; Lin HN; Tsai SJ; Lee YC; Chen YS
    J Formos Med Assoc; 2003 Jan; 102(1):30-6. PubMed ID: 12684609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms.
    Kämpf P; Agelink MW; Naber D
    Pharmacopsychiatry; 2005 Jan; 38(1):39-40. PubMed ID: 15706467
    [No Abstract]   [Full Text] [Related]  

  • 16. Amisulpride in schizophrenia.
    Reid S; Turner J
    Br J Psychiatry; 1998 May; 172():450. PubMed ID: 9747415
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study.
    Surguladze S; Patel A; Kerwin RW; Knapp M; Travis MJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):517-22. PubMed ID: 15866352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment.
    Chen CY; Yeh YW; Kuo SC; Ho PS; Liang CS; Yen CH; Lu RB; Huang SY
    Psychoneuroendocrinology; 2016 Mar; 65():67-75. PubMed ID: 26724569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.